Difference between revisions of "Cerwenka 2016 Mol Cell Oncol"
From Bioblast
(Created page with "{{Publication |title=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538. |info=[https...") Β |
Β |
||
(One intermediate revision by one other user not shown) | |||
Line 1: | Line 1: | ||
{{Publication | {{Publication | ||
|title=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538. Β | |title=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538. | ||
|info=[https://www.ncbi.nlm.nih.gov/pubmed/27652323 PMID: 27652323] | |info=[https://www.ncbi.nlm.nih.gov/pubmed/27652323 PMID: 27652323] | ||
|authors=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G | |authors=Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G | ||
|year=2016 | |year=2016 | ||
|journal=Mol Cell Oncol | |journal=Mol Cell Oncol | ||
|abstract=Targeting tumor glycolysis would hit the main energy source of cancer. We show that natural killer (NK) cells pursue this strategy by employing high mobility group box 1 (HMGB1) protein-a well-known proinflammatory cytokine-to specifically target glycolysis in cancer cells. This opens up new perspectives for cancer immunotherapy. Β | |abstract=Targeting tumor glycolysis would hit the main energy source of cancer. We show that natural killer (NK) cells pursue this strategy by employing high mobility group box 1 (HMGB1) protein-a well-known proinflammatory cytokine-to specifically target glycolysis in cancer cells. This opens up new perspectives for cancer immunotherapy. | ||
|keywords=Cancer, HMGB1, NK cells, Natural killer cells, Cell death, Immunotherapy, Innate immunity, Metabolism | |keywords=Cancer, HMGB1, NK cells, Natural killer cells, Cell death, Immunotherapy, Innate immunity, Metabolism, HT29 colon carcinoma cells | ||
}} | }} | ||
{{Labeling | {{Labeling | ||
|area=Respiration | |area=Respiration | ||
|diseases=Cancer | |diseases=Cancer | ||
|tissues=Endothelial;epithelial;mesothelial cell | |organism=Human | ||
|tissues=Endothelial;epithelial;mesothelial cell, Other cell lines | |||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional= | |additional=2016-11, | ||
}} | }} |
Latest revision as of 12:35, 9 November 2017
Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) HMGB1: The metabolic weapon in the arsenal of NK cells. Mol Cell Oncol 3:e1175538. |
Cerwenka A, Kopitz J, Schirmacher P, Roth W, Gdynia G (2016) Mol Cell Oncol
Abstract: Targeting tumor glycolysis would hit the main energy source of cancer. We show that natural killer (NK) cells pursue this strategy by employing high mobility group box 1 (HMGB1) protein-a well-known proinflammatory cytokine-to specifically target glycolysis in cancer cells. This opens up new perspectives for cancer immunotherapy. β’ Keywords: Cancer, HMGB1, NK cells, Natural killer cells, Cell death, Immunotherapy, Innate immunity, Metabolism, HT29 colon carcinoma cells
Labels: MiParea: Respiration
Pathology: Cancer
Organism: Human Tissue;cell: Endothelial;epithelial;mesothelial cell, Other cell lines
HRR: Oxygraph-2k
2016-11